Bay Street May Open With Negative Bias

Canadian shares are likely to open with a negative bias on Thursday, weighed down by weak guidance from Facebook parent Alphabet, and disappointing results from IBM. Higher crude oil prices may trigger some buying in the energy sector and limit market\'s downside. Investors will also be reacting to a slew of earnings updates from Canadian...

Read More

U.S. Weekly Jobless Claims Unexpectedly Decrease

The Labor Department released a report on Thursday showing an unexpected decrease by first-time claims for U.S. unemployment benefits in the week ended April 20th. The report said initial jobless claims fell to 207,000, a decrease of 5,000 from the previous week\'s unrevised level of 212,000. The dip surprised economists, who had expected jobless claims...

Read More

U.S. Dollar Falls Against Euro, Pound

The U.S. dollar weakened against the euro and the pound in the Asian session on Wednesday. The U.S. dollar fell to nearly a 1-week low of 1.0715 against the euro, from yesterday\'s closing value of 1.0699. Against the pound, the greenback slid to a 5-day low of 1.2465 from Tuesday\'s closing value of 1.2448. If...

Read More

Yen Declines To Multi-decade Low

The Japanese yen weakened against their major currencies in the Asian session on Wednesday, as markets expect currency intervention by Japanese authorities to prop up the currency ahead of this week\'s Bank of Japan policy meeting. Traders await the BOJ\'s two-day policy meeting starts on Thursday for cues on when the central bank will raise...

Read More

Asian Markets Climb Led By Tech Stocks

Asian stocks advanced on Wednesday as focus remained on earnings reports from the U.S. megacaps due this week. Facebook owner Meta Platforms will declare its first-quarter earnings later today, while Microsoft and Alphabet will report their financial results on Thursday. Electric vehicle giant Tesla announced plans to introduce new vehicle models earlier than previously anticipated,...

Read More

Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism

Danish pharmaceutical company Ascendis Pharma A/S (ASND) announced that the United Kingdom\'s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH (palopegteriparatide; developed as TransCon PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism The MHRA has also granted YORVIPATH...

Read More